4-(3-Dibenzylamino-2-hydroxy-propoxy)-benzimidazol-2-on | 64208-93-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 4-(3-Dibenzylamino-2-hydroxy-propoxy)-benzimidazol-2-on
• 英文别名: 4-(3-dibenzylamino-2-hydroxy-propoxy)-1,3-dihydro-benzoimidazol-2-one；4-[2-Hydroxy-3-(N,N dibenzylamino)propoxy]-1,3-dihydro-2H-benzimidazol-2-one；4-[3-(dibenzylamino)-2-hydroxypropoxy]-1,3-dihydrobenzimidazol-2-one
• CAS: 64208-93-1
• 化学式: C₂₄H₂₅N₃O₃
• 分子量: 403.481
• InChiKey: WDOAGMBPXQBNIN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  30
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  73.8
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(3-Dibenzylamino-2-hydroxy-propoxy)-benzimidazol-2-on 、 甲酸铵 在 钯 甲醇 作用下， 以 甲醇 为溶剂， 反应 3.0h， 以to give 1.56 g (65%) as the desired product of a pale grey solid的产率得到(S)-4-[2-hydroxy-3-aminopropoxy]-1,3-dihydro-2H-benzimidazol-2-one
  参考文献：
  名称：

  Selective .beta.-3 adrenergic agonists

  摘要：

  本发明属于医学领域，特别是用于治疗II型糖尿病和肥胖症。更具体地说，本发明涉及选择性β3肾上腺素能受体激动剂，用于治疗II型糖尿病和肥胖症。本发明提供了化合物和治疗II型糖尿病的方法，包括向需要该化合物的哺乳动物施用I和II式化合物：##STR1##

  公开号：

  US06093735A1

文献信息

• Selective beta3 adrenergic agonists
  申请人：ELI LILLY AND COMPANY

  公开号：EP0764640A1

  公开（公告）日：1997-03-26

  The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective β3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formulas I and II:

  本发明属于医学领域，特别是在治疗2型糖尿病和肥胖方面。更具体地说，本发明涉及对选择性β3肾上腺素能受体激动剂在治疗2型糖尿病和肥胖方面的应用。该发明提供了化合物和治疗2型糖尿病的方法，包括向需要的哺乳动物施用具有I和II式的化合物。
• Selective .beta.3 adrenergic agonists
  申请人：Eli Lilly and Company

  公开号：US05786356A1

  公开（公告）日：1998-07-28

  The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formulas I and II: ##STR1##

  本发明涉及医学领域，特别是在治疗II型糖尿病和肥胖症方面。更具体地说，本发明涉及选择性β3肾上腺素能受体激动剂，可用于治疗II型糖尿病和肥胖症。本发明提供了化合物和治疗II型糖尿病的方法，包括将式I和式II的化合物用于治疗需要的哺乳动物：##STR1##
• Selective &bgr;3 adrenergic agonists
  申请人：Eli Lilly and Company

  公开号：US06265581B1

  公开（公告）日：2001-07-24

  The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective &bgr;3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formulas I and II:

  本发明属于医学领域，特别是用于治疗II型糖尿病和肥胖症。更具体地说，本发明涉及选择性β3肾上腺素能受体激动剂，用于治疗II型糖尿病和肥胖症。本发明提供了化合物和治疗II型糖尿病的方法，包括向需要的哺乳动物注射式I和式II的化合物。
• Selective .beta..sub.3 adrenergic agonists
  申请人：Eli Lilly and Company

  公开号：US06075040A1

  公开（公告）日：2000-06-13

  The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formulas I and II: ##STR1##

  本发明涉及医学领域，特别是在治疗II型糖尿病和肥胖症方面。更具体地说，本发明涉及选择性β3肾上腺素受体激动剂，用于治疗II型糖尿病和肥胖症。该发明提供了化合物和治疗II型糖尿病的方法，包括向需要的哺乳动物中给予公式I和II的化合物： ##STR1##
• Selective .beta.3 adrenergic agonist
  申请人：Eli Lilly and Company

  公开号：US05977154A1

  公开（公告）日：1999-11-02

  The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formulas I and II: ##STR1##

  本发明属于医学领域，特别是用于治疗2型糖尿病和肥胖症。更具体地说，本发明涉及选择性β3肾上腺素受体激动剂，用于治疗2型糖尿病和肥胖症。本发明提供了化合物和治疗2型糖尿病的方法，包括向需要的哺乳动物注射式I和II的化合物：##STR1##